9.13
price up icon0.44%   0.04
after-market Handel nachbörslich: 8.94 -0.19 -2.08%
loading

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
09:02 AM

REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey

09:02 AM
pulisher
Jul 23, 2025

What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives REGENXBIO Inc. stock priceOverwhelming profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 11, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News

Jul 10, 2025
pulisher
Jul 09, 2025

Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com

Jul 09, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛

Jul 08, 2025
pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025
pulisher
Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech

Jun 05, 2025
pulisher
Jun 05, 2025

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg

Jun 05, 2025
pulisher
Jun 05, 2025

Transcript : REGENXBIO Inc.Special Call - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus

Jun 05, 2025
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):